Clinical Trial Update: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

This update covers a Phase 2 study evaluating the combination of guselkumab and golimumab in participants with moderately to severely active ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Simponi (golimumab)
• TREMFYA (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colitis, Ulcerative | Phase 2 | Status: ACTIVE_NOT_RECRUITING